Sanofi’s Genzyme Bid May Need to Reach $80 to Win Investors - BusinessWeek: "Sanofi-Aventis SA may have to pay at least $80 a share, or $21.3 billion, to acquire genetic-disease drugmaker Genzyme Corp. as activist directors drive up the price, investors in the U.S. biotechnology company say.
- Sent using Google Toolbar"
No comments:
Post a Comment